ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AT9283. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

24 träffar

Bibliografisk träff 2024-08-20

Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer.

Piastra V, Ganci F, Sacconi A, Pranteda A, Allegretti M, Bernardini R, Serra M, Lupo B, Dell'Aquila E, Ferretti G, Pescarmona E, Bartolazzi A, Blandino G, Trusolino L, Bossi G.

J Exp Clin Cancer Res · research-article; journal article · DOI 10.1186/s13046-024-03150-4

Bibliografisk träff 2024-02-27

DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.

Chen M, Zhang S, Wang F, He J, Jiang W, Zhang L.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12967-024-04910-8

Bibliografisk träff 2023-12-11

The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect.

Jiang K, Bai L, Wang C, Xiao X, Cheng Z, Peng H, Liu S.

PeerJ · research support, non-u.s. gov't; research-article; journal article · DOI 10.7717/peerj.16581

Bibliografisk träff 2022-11-01

AT9283, 1-Cyclopropyl-3-(3-(5-(Morpholinomethyl)-1H-Benzo[d]Imidazole-2-yl)-1H-Pyrazol-4-yl) Urea, Inhibits Syk to Suppress Mast Cell-Mediated Allergic Response.

Kim SJ, Choi MY, Min KY, Jo MG, Kim JM, Kim HS, Kim YM.

Biomol Ther (Seoul) · research-article; journal article · DOI 10.4062/biomolther.2022.042

Bibliografisk träff 2020-09-25

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.

Torrente L, Maan G, Oumkaltoum Rezig A, Quinn J, Jackson A, Grilli A, Casares L, Zhang Y, Kulesskiy E, Saarela J, Bicciato S, Edwards J, Dinkova-Kostova AT, de la Vega L.

Biomolecules · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/biom10101365

Bibliografisk träff 2020-08-18

AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.

Takeda T, Tsubaki M, Genno S, Nemoto C, Onishi Y, Yamamoto Y, Imano M, Satou T, Nishida S.

Oncol Rep · journal article · DOI 10.3892/or.2020.7739

Bibliografisk träff 2017-03-05

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.

Duong JK, Griffin MJ, Hargrave D, Vormoor J, Edwards D, Boddy AV.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/bcp.13260

Bibliografisk träff 2016-12-01

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.

Pediatr Blood Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1002/pbc.26351

Bibliografisk träff 2015-12-01

Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.

Moawad EY.

J Gastrointest Cancer · journal article · DOI 10.1007/s12029-015-9761-9

Bibliografisk träff 2015-10-15

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T.

Leuk Lymphoma · letter; clinical trial, phase ii · DOI 10.3109/10428194.2015.1091927

Bibliografisk träff 2014-11-04

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D.

Clin Cancer Res · multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-14-1592

Bibliografisk träff 2014-08-10

Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.

Petersen W, Liu J, Yuan L, Zhang H, Schneiderjan M, Cho YJ, MacDonald TJ.

Cancer Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2014.07.038

Bibliografisk träff 2013-11-14

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.

Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H.

Clin Lymphoma Myeloma Leuk · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1016/j.clml.2013.11.001

Bibliografisk träff 2013-09-27

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-013-0018-9

Bibliografisk träff 2012-02-09

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.

Shah M, Gallipoli P, Lyons J, Holyoake T, Jørgensen H.

Blood Cells Mol Dis · letter; research support, non-u.s. gov't · DOI 10.1016/j.bcmd.2012.01.005

Bibliografisk träff 2011-11-19

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D.

Int J Cancer · journal article; research support, n.i.h., extramural · DOI 10.1002/ijc.26324

Bibliografisk träff 2011-10-19

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I.

Ann Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdr451

Bibliografisk träff 2011-06-12

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.

Podesta JE, Sugar R, Squires M, Linardopoulos S, Pearson AD, Moore AS.

Leuk Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2011.05.022

Bibliografisk träff 2011-03-23

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-10-3012

Bibliografisk träff 2010-12-01

AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.

Kimura S.

Curr Opin Investig Drugs · review; journal article

Bibliografisk träff 2010-06-14

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2009-03-211466

Bibliografisk träff 2010-05-07

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.

Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, Scott MA, Smyth T, Squires MS, Thompson NT, Green AR, Wallis NG.

Br J Haematol · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2141.2010.08175.x

Bibliografisk träff 2009-06-15

Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N.

Cell Cycle · journal article · DOI 10.4161/cc.8.12.8741

Bibliografisk träff 2009-01-01

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinković M, Wyatt PG.

J Med Chem · journal article · DOI 10.1021/jm800984v